Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Drug-Drug Interaction Study of NS-229 in Healthy Male Subjects
jRCT2071250080Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NS-229 (3 arms), sponsored by Nippon Shinyaku. Primary endpoint: Primary PK parameters of NS-229 and combination drugs. Started Oct 2025; status: completed.
02
Drugs
NS-229
Beyond the preview
Go deeper on jRCT2071250080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250080.